unanswered questions regarding the use of parp inhibitors for patients with mcrpc
Published 1 year ago • 16 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
1:01
choosing the correct parp inhibitor for prostate cancer
-
1:53
the evolving role of parp inhibitors in mcrpc
-
1:39
challenges in the field of parpi treatment for mcrpc
-
2:30
parp inhibitors plus novel endocrine agents for patients with metastatic prostate cancer
-
2:23
dr. moore on unanswered questions with parp inhibitors in ovarian cancer
-
3:39
dna damage response
-
12:24
the role of targeting dna repair with parp
-
50:29
the parp revolution: how parp inhibitors are changing the landscape of ovarian cancer treatment
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
1:41
dr gong on the frontline use of parp inhibitors in mcrpc
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
2:25
dr. naumann on unanswered questions with parp inhibitors in ovarian cancer
-
0:57
when is the optimal time to use parp inhibitors in prostate cancer patients?
-
2:09
current perspectives from clinical trials using parp inhibitors for prostate cancer
-
4:56
improving the prognosis for patients with mcrpc
-
11:49
brca & parp inhibitors: targeted chemotherapy | #markscholzmd #alexscholz @pcri
-
2:31
should all platinum sensitive patients recieve parp inhibitors?
-
1:31
tackling disease progression whilst using parp inhibitors for prostate cancer
-
4:02
the emerging role of parp inhibitors in prostate cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
0:47
dr. morgan on the role of parp inhibitors in prostate cancer
-
1:43
parp inhibitors for prostate cancer